IPCA Laboratories Share Price

NSE: IPCALAB

₹ 1,762.70

-₹8.50 (-0.48%)

Last updated 24 Jul, 2026, 15:47 IST

IPCA Laboratories Share Price Today

As of 26 Jul 2026, IPCA Laboratories share price is ₹1,762.70. The stock opened at ₹1,765.00, compared to its previous close of ₹1,771.20. During today's trading session, IPCA Laboratories share price moved in the range of ₹1,747.00 to ₹1,788.90, with an average price of ₹1,767.95 for the day. Looking at its last 52-week, the stock has touched a low of ₹1,251.60 and a high of ₹1,944.90. On the performance front, IPCA Laboratories share price has increased by 20.50% over the last six months and is up 14.40% on a year-on-year basis.

₹1,747.00

0.48% down today

₹1,788.90

1D LOW

1D HIGH

Latest Earning

Op Profit TrendUp by 39.02% YoY

Latest Earning

Net Profit TrendUp by 51.28% YoY

Latest Earning

Revenue TrendUp by 2.88% QoQ

Stock Performance

OutperformingBeat Nifty by 9.79 % in last 1 month

Shareholding Pattern

DIIDII increased stake by 0.10%

Shareholding Pattern

FIIFII increased stake by 0.93%

IPCA Laboratories Returns Calculator

If you would've invested

₹

₹1,000₹1Cr

Historical Returns

1 Year

₹5,84,062+₹84,062 (+16.81%)

3 Year

₹10,08,987+₹5,08,987 (+101.80%)

5 Year

₹8,37,626+₹3,37,626 (+67.53%)

₹1,410.20₹2,115.20

Circuit Low

Circuit High

₹1,251.60₹1,944.90

52-Week Low

52-Week High

Circuit

₹1,410.20

₹2,115.20

52-week

₹1,251.60

₹1,944.90

Mkt Cap Cr

44,720.40

P/E

35.64

P/B

5.04

ROE

15.87%

D/E

0.08

ROCE

19.01%

Div. Yield

0.37%

EPS(TTM)

45.84

Turnover

0.88

EV/EBITDA

19.77

Net Margin

15.44%

Op. Margin

25.17%

ROA

10.94%

Quick Ratio

1.61

Curr. Ratio

2.08

Mkt Cap Cr

44,720.40

P/E

35.64

P/B

5.04

ROE

15.87%

D/E

0.08

ROCE

19.01%

Div. Yield

0.37%

EPS(TTM)

45.84

Turnover

0.88

EV/EBITDA

19.77

Net Margin

15.44%

Op. Margin

25.17%

ROA

10.94%

Quick Ratio

1.61

Curr. Ratio

2.08

Based on fundamentals, this stock's

Performance

Excellent

Ipca Labs. outperforming all market indices

Valuation

Fairly Valued

Ipca Labs. appears to be fairly valued compared to its peers

Earnings

Good

Ipca Labs. revenue, operating profit and net profit are growing

Peer Comparison

Peer comparison — key ratios
Name	Mkt Cap Cr	P/E	P/B	ROE	D/E	ROCE	Book Value	Div. Yield	Turnover	EPS(TTM)
Sun Pharmaceutical Industries	4,65,711.00	36.73	5.05	14.85%	0.55	18.72%	18.85	0.91%	0.56	10.90
Divis Laboratories	1,92,376.00	61.36	9.40	16.19%	0.00	21.00%	9.43	0.50%	0.58	98.19
Torrent Pharmaceuticals	1,88,655.00	66.03	17.03	26.76%	1.05	18.30%	16.90	0.90%	0.49	64.75
Cipla	1,13,979.00	33.96	3.31	11.27%	0.00	14.95%	423.36	0.92%	0.45	43.52
Zydus Lifesciences	1,10,613.00	17.39	3.23	19.69%	0.35	20.30%	3.70	0.11%	0.39	35.38
Lupin	1,08,339.00	19.83	4.71	27.01%	0.03	27.44%	3.51	0.78%	0.61	129.18
Mankind Pharma	1,03,472.00	1.05	0.12	12.65%	0.42	12.97%	5.05	0.05%	0.54	49.37
Dr. Reddy's Laboratories	96,204.70	30.22	2.53	11.07%	0.18	12.54%	377.96	0.69%	0.41	38.68
Aurobindo Pharma	88,949.80	25.39	2.35	9.25%	0.19	11.76%	391.14	0.26%	0.48	41.58
Laurus Labs	86,564.20	79.36	16.33	16.77%	0.40	16.14%	97.21	0.12%	0.67	13.72

IPCA Laboratories Financials

Full statement

Income Statement · Consolidated

Income Statement · Consolidated — all values in INR Crore
Particulars	Mar 2026	Mar 2025	Mar 2024	Mar 2023
Revenue	₹9,646.33	₹8,939.59	₹7,705.04	₹6,244.32
Other Income	₹174.45	₹92.80	₹124.77	₹125.62
Total Revenue	₹9,820.78	₹9,032.39	₹7,829.81	₹6,369.94
Total Expenses	₹8,161.83	₹7,696.20	₹6,879.39	₹5,624.65
Profit Before Tax	₹1,572.52	₹1,131.14	₹842.67	₹745.29
Tax	₹381.15	₹343.61	₹313.46	₹253.36
Profit After Tax	₹1,191.37	₹787.53	₹529.21	₹491.93
EPS - Basic	₹44.98	₹29.08	₹21.57	₹18.58
EPS - Diluted	₹44.98	₹29.08	₹21.57	₹18.58

Cash Flow · Consolidated

Cash Flow · Consolidated — all values in INR Crore
Particulars	Mar 2026	Mar 2025	Mar 2024	Mar 2023
Profit before tax	₹1,572.52	₹1,131.14	₹842.67	₹745.29
Income before WC changes	₹1,849.87	₹1,859.03	₹1,332.54	₹980.47
Change in Assets	-₹280.16	-₹192.84	-₹185.45	₹88.73
Change in Liabilities	-₹13.79	₹16.38	₹93.86	-₹39.74
Change in WC	-₹293.95	-₹176.46	-₹91.59	₹48.99
Cash flow from Operations	₹1,141.97	₹1,321.32	₹944.65	₹805.81
Cash flow from Investing	-₹246.77	-₹869.50	-₹1,291.79	-₹725.00
Cash flow from Financing	-₹753.53	-₹282.98	-₹552.55	₹507.24
Total Cash Flow	₹141.67	₹168.84	-₹899.69	₹588.05
Cash (Start of the year)	₹924.63	₹755.79	₹1,578.98	₹990.93
Cash (End of the year)	₹1,066.30	₹924.63	₹755.79	₹1,578.98

Balance Sheet · Consolidated

Balance Sheet · Consolidated — all values in INR Crore
Particulars	Mar 2026	Mar 2025	Mar 2024	Mar 2023
Non-Current Assets	₹5,996.58	₹5,793.51	₹5,565.73	₹3,437.16
Current Assets	₹6,373.61	₹5,967.04	₹5,535.55	₹5,189.27
Total Assets	₹12,370.19	₹11,760.55	₹11,101.28	₹8,626.43
Current Liabilities	₹2,306.93	₹2,386.22	₹2,355.64	₹1,805.82
Net Current Asset	₹4,066.68	₹3,580.82	₹3,179.91	₹3,383.45
Non-Current Liabilities	₹539.20	₹986.06	₹1,018.64	₹905.29
Equity Capital	₹9,524.06	₹8,388.27	₹7,727.00	₹5,915.32
Total Equity & Liabilities	₹12,370.19	₹11,760.55	₹11,101.28	₹8,626.43

Income Statement · Standalone

Income Statement · Standalone — all values in INR Crore
Particulars	Mar 2026	Mar 2025	Mar 2024	Mar 2023
Revenue	₹7,336.75	₹6,677.92	₹6,166.46	₹5,814.62
Other Income	₹94.64	₹71.29	₹111.29	₹111.19
Total Revenue	₹7,431.39	₹6,749.21	₹6,277.75	₹5,925.81
Total Expenses	₹5,868.84	₹5,467.90	₹5,322.23	₹5,175.32
Profit Before Tax	₹1,532.13	₹999.77	₹822.16	₹750.49
Tax	₹399.61	₹349.01	₹291.75	₹244.79
Profit After Tax	₹1,132.52	₹650.76	₹530.41	₹505.70
EPS - Basic	₹44.64	₹25.65	₹20.91	₹19.93
EPS - Diluted	₹44.64	₹25.65	₹20.91	₹19.93

Cash Flow · Standalone

Cash Flow · Standalone — all values in INR Crore
Particulars	Mar 2026	Mar 2025	Mar 2024	Mar 2023
Profit before tax	₹1,532.13	₹999.77	₹822.16	₹750.49
Income before WC changes	₹1,905.74	₹1,605.55	₹1,221.32	₹956.58
Change in Assets	-₹296.30	₹43.76	-₹160.96	₹70.75
Change in Liabilities	₹162.62	₹49.51	₹47.10	-₹49.79
Change in WC	-₹133.68	₹93.27	-₹113.86	₹20.96
Cash flow from Operations	₹1,378.12	₹1,374.07	₹830.51	₹762.29
Cash flow from Investing	-₹696.99	-₹738.81	-₹1,355.18	-₹709.61
Cash flow from Financing	-₹745.21	-₹428.44	-₹464.88	₹506.38
Total Cash Flow	-₹64.08	₹206.82	-₹989.55	₹559.06
Cash (Start of the year)	₹722.10	₹515.28	₹1,504.83	₹945.77
Cash (End of the year)	₹658.02	₹722.10	₹515.28	₹1,504.83

Balance Sheet · Standalone

Balance Sheet · Standalone — all values in INR Crore
Particulars	Mar 2026	Mar 2025	Mar 2024	Mar 2023
Non-Current Assets	₹5,780.50	₹5,290.98	₹5,149.38	₹3,571.82
Current Assets	₹3,995.00	₹3,779.94	₹3,509.89	₹4,875.15
Total Assets	₹9,775.50	₹9,070.92	₹8,659.27	₹8,446.97
Current Liabilities	₹1,418.75	₹1,419.53	₹1,520.17	₹1,677.78
Net Current Asset	₹2,576.25	₹2,360.41	₹1,989.72	₹3,197.37
Non-Current Liabilities	₹377.40	₹759.77	₹790.39	₹891.89
Equity Capital	₹7,979.35	₹6,891.62	₹6,348.71	₹5,877.30
Total Equity & Liabilities	₹9,775.50	₹9,070.92	₹8,659.27	₹8,446.97

* All values are in INR Crore

Qty

Bid

Ask

Qty

1762.7

Bid Total: 0

Ask Total: 40

Buy orders: 0%

Sell orders: 100%

30 levels of bid & ask depth

Supply & Demand Zones

Bearish

Neutral

Bullish

Slightly Bullish

by SEBI experts available for this stock

Earn more using advisory

by SEBI experts

Expert Pick

EXPPICK

Stop-loss

Entry price

Target

Indicator

Value

Verdict

RSI (14)

52.04

Neutral

ATR (14)

58.95

Neutral

STOCH(9,6)

15.92

Bullish

STOCH RSI (14)

Bullish

ADX(9)

36.58

Bearish

UO(9)

47.29

Neutral

ROC(12)

0.02

Bullish

WillR(14)

-84.08

Bullish

Period

Simple value

Exponential vaue

1792

1790.7

10D

1829.25

1799.92

20D

1786.58

1773.4

50D

1670.58

1692.57

100D

1593.82

1617.15

About IPCA Laboratories

ISIN

INE571A01038

Sector Market Cap

₹ 44,720.4 Cr

Ipca Laboratories Limited is an India-based integrated pharmaceutical company. The Company is engaged in manufacturing and marketing over 350 formulations and approximately 80 active pharmaceutical ingredients (APIs) covering various therapeutic segments. It offers APIs, such as Atenolol, Chloroquine Phosphate, Chlorthalidone, Furosemide, Hydroxychloroquine sulfate, Losartan, Metoprolol Succinate, Metoprolol Tartrate, Pyrantel Salts and Propranolol. The Company offers brands, such as Zerodol, Lariago, HCQS, Perinorm, Rapither AB, Tenoric, Lumerax, Etova, Fexova, Malirid, Allsuth, Alwiz, AZR 50mg, Bacilon, Cinkona, Clarbact, Glyree MV, Halotop, Luliz, Ozepam, Pacimol, Pari, Xtor-F, Zabpro, Zilast, Ramcor, Sove, Venpower and Folitrax. The Company’s products are sold in over 100 countries across the globe. The Company has 18 manufacturing units in India manufacturing APIs and formulations. Its subsidiaries include Ipca Pharmaceuticals, Inc. and Ipca Pharma Nigeria Ltd.

IPCA Laboratories Financial Highlights

Revenue: IPCA Laboratories reported revenue of ₹9,820.78 crore in FY26 vs ₹9,032.39 crore in FY25. It showed an increase of 8.73% on a yearly basis.
Operating Profit: IPCA Laboratories reported an operating profit of ₹1,572.52 crore in FY26 vs ₹1,131.14 crore in FY25. It showed an increase of 39.02% on a year-on-year basis.
Net Profit: IPCA Laboratories reported a net profit of ₹1,191.37 crore in FY26 vs ₹787.53 crore in FY25. It showed an increase of 51.28% on a yearly basis.

IPCA Laboratories Quarterly Result Highlights

IPCA Laboratories reported revenue of ₹2,482.22 crore in Mar 2026, compared with ₹2,412.69 crore in Dec 2025, representing an increase of 2.88% on a quarter-on-quarter (QoQ) basis.
IPCA Laboratories reported an operating profit of ₹404.45 crore in Mar 2026, compared with ₹445.98 crore in Dec 2025, representing a decrease of 9.31% on a quarter-on-quarter (QoQ) basis.
IPCA Laboratories reported a profit of ₹309.40 crore in Mar 2026, compared with ₹364.05 crore in Dec 2025, reflecting a decrease of 15.01% on a QoQ basis.
The earnings per share (EPS) of IPCA Laboratories stood at ₹44.98 during Mar 2026.